« Previous
Next »
Journal of Hepatology
Volume 48
, Pages
S38-S57
, 2008
The challenges in primary sclerosing cholangitis – Aetiopathogenesis, autoimmunity, management and malignancy
-
Typical examples of PSC cholangiograms. (A) Type I intrahepatic alterations, (B) Type II intraheptic alterations, (C) Type III intraheptic alterations.
Typical examples of PSC cholangiograms. (A) Type I intrahepatic alterations, (B) Type II intraheptic alterations, (C) Type III intraheptic alterations.
-
Secondary biliary sclerosis can mimick cholangiographic features of PSC. (A) The cholangiogram of a patient with ischemic-like cholangiopathy and biliary cast formation after prolonged anamnestic poly
Secondary biliary sclerosis can mimick cholangiographic features of PSC. (A) The cholangiogram of a patient with ischemic-like cholangiopathy and biliary cast formation after prolonged anamnestic polytrauma with sepsis and mechanical ventilation. (B) A biliary cast that had been removed from the hepatic duct in this patient.
-
ERC with the corresponding MRC of two patients with PSC. Patient A presents with multifocal strictures of the intrahepatic bile ducts and with a high-grade stenosis at the cystic duct junction. PatienERC with the corresponding MRC of two patients with PSC. Patient A presents with multifocal strictures of the intrahepatic bile ducts and with a high-grade stenosis at the cystic duct junction. Patient B features a long-segment filiform stenosis of the common bile duct; the intrahepatic ducts seem to be profoundly narrowed in ERC while MRC accentuates the dilated bile ducts in intervening segments.
-
Kaplan–Meier analysis of cumulative survival after liver transplantation from 01/2003 to 08/2007 at Hannover Medical School comparing 55 patients with PSC (incl. five patients with CC) and 318 patientKaplan–Meier analysis of cumulative survival after liver transplantation from 01/2003 to 08/2007 at Hannover Medical School comparing 55 patients with PSC (incl. five patients with CC) and 318 patients with other chronic liver diseases (hepatitis B and C, alcoholic liver disease, hepatocellular carcinoma and others). The log-rank-test shows a significant better survival of patients with PSC (p
<
0.01).
☆ The Authors T.J. Weismüller, J. Wedemeyer, C.P. Strassburg and S. Kubicka state that they have nothing to declare regarding conflict of interest and funding with respect to this manuscript. M.P. Manns is an investigator/consultant/speaker at Novartis, Roche, Schering-Plough, Gilead Sciences Inc., Tibotec, Vertex, GlaxoSmithKline, Boehringer Ingelheim, Bristol-Myers Squibb, Idenix and Merck. M.P. Manns received meeting support and lecture fees from the Falk Foundation, Freiburg, Germany. M.P. Manns received funding from Deutsche Forschungsgemeinschaft (KF0119, SFB 621, SFB738), DFG Cluster of Excellence “Rebirth” and Transplantation centre.
PII: S0168-8278(08)00059-7
doi: 10.1016/j.jhep.2008.01.020
© 2008 European Association for the Study of the Liver. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Journal of Hepatology
Volume 48
, Pages
S38-S57
, 2008
